MDNAF
Price
$0.60
Change
-$0.02 (-3.23%)
Updated
Aug 1 closing price
Capitalization
50.65M
6 days until earnings call
STOK
Price
$12.91
Change
+$0.06 (+0.47%)
Updated
Aug 1 closing price
Capitalization
705.39M
9 days until earnings call
Interact to see
Advertisement

MDNAF vs STOK

Header iconMDNAF vs STOK Comparison
Open Charts MDNAF vs STOKBanner chart's image
Medicenna Therapeutics
Price$0.60
Change-$0.02 (-3.23%)
Volume$170.65K
Capitalization50.65M
Stoke Therapeutics
Price$12.91
Change+$0.06 (+0.47%)
Volume$426.88K
Capitalization705.39M
MDNAF vs STOK Comparison Chart in %
Loading...
MDNAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDNAF vs. STOK commentary
Aug 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDNAF is a Hold and STOK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (MDNAF: $0.60 vs. STOK: $12.91)
Brand notoriety: MDNAF and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDNAF: 517% vs. STOK: 65%
Market capitalization -- MDNAF: $50.65M vs. STOK: $705.39M
MDNAF [@Biotechnology] is valued at $50.65M. STOK’s [@Biotechnology] market capitalization is $705.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $213.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDNAF’s FA Score shows that 0 FA rating(s) are green whileSTOK’s FA Score has 1 green FA rating(s).

  • MDNAF’s FA Score: 0 green, 5 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than MDNAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDNAF’s TA Score shows that 4 TA indicator(s) are bullish while STOK’s TA Score has 4 bullish TA indicator(s).

  • MDNAF’s TA Score: 4 bullish, 3 bearish.
  • STOK’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MDNAF is a better buy in the short-term than STOK.

Price Growth

MDNAF (@Biotechnology) experienced а -2.31% price change this week, while STOK (@Biotechnology) price change was -1.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.14%. For the same industry, the average monthly price growth was +15.55%, and the average quarterly price growth was +36.18%.

Reported Earning Dates

MDNAF is expected to report earnings on Nov 14, 2025.

STOK is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+0.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($705M) has a higher market cap than MDNAF($50.7M). STOK YTD gains are higher at: 17.044 vs. MDNAF (-47.598). STOK has higher annual earnings (EBITDA): 40.3M vs. MDNAF (-18.65M). STOK has more cash in the bank: 357M vs. MDNAF (30M). MDNAF has less debt than STOK: MDNAF (174K) vs STOK (2.35M). STOK has higher revenues than MDNAF: STOK (191M) vs MDNAF (0).
MDNAFSTOKMDNAF / STOK
Capitalization50.7M705M7%
EBITDA-18.65M40.3M-46%
Gain YTD-47.59817.044-279%
P/E RatioN/A15.76-
Revenue0191M-
Total Cash30M357M8%
Total Debt174K2.35M7%
FUNDAMENTALS RATINGS
MDNAF vs STOK: Fundamental Ratings
MDNAF
STOK
OUTLOOK RATING
1..100
280
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
54
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9840
PRICE GROWTH RATING
1..100
8944
P/E GROWTH RATING
1..100
10021
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDNAF's Valuation (40) in the null industry is in the same range as STOK (54). This means that MDNAF’s stock grew similarly to STOK’s over the last 12 months.

MDNAF's Profit vs Risk Rating (100) in the null industry is in the same range as STOK (100). This means that MDNAF’s stock grew similarly to STOK’s over the last 12 months.

STOK's SMR Rating (40) in the null industry is somewhat better than the same rating for MDNAF (98). This means that STOK’s stock grew somewhat faster than MDNAF’s over the last 12 months.

STOK's Price Growth Rating (44) in the null industry is somewhat better than the same rating for MDNAF (89). This means that STOK’s stock grew somewhat faster than MDNAF’s over the last 12 months.

STOK's P/E Growth Rating (21) in the null industry is significantly better than the same rating for MDNAF (100). This means that STOK’s stock grew significantly faster than MDNAF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDNAFSTOK
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 11 days ago
84%
Bullish Trend 11 days ago
86%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 1 day ago
78%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
MDNAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WWIAX12.19N/A
N/A
Westwood Income Opportunity A
SHSCX44.55N/A
N/A
BlackRock Health Sciences Opps Inv C
BUFEX59.30N/A
N/A
Buffalo Blue Chip Growth
SLYCX15.72N/A
N/A
SEI Large Cap Y (SIMT)
OWLLX10.79N/A
N/A
Channing Intrinsic Value Sm-Cp Instl

MDNAF and

Correlation & Price change

A.I.dvisor tells us that MDNAF and LRMR have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MDNAF and LRMR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDNAF
1D Price
Change %
MDNAF100%
-2.58%
LRMR - MDNAF
25%
Poorly correlated
-0.58%
VIR - MDNAF
25%
Poorly correlated
-0.79%
STOK - MDNAF
23%
Poorly correlated
+0.47%
CGEM - MDNAF
23%
Poorly correlated
-1.29%
PTCT - MDNAF
22%
Poorly correlated
+0.04%
More